NasdaqCM:NKTRPharmaceuticals
Assessing Nektar Therapeutics (NKTR) Valuation After Positive REZOLVE AD Data And Major Equity Financing
Nektar Therapeutics (NKTR) is back on investors’ radar after reporting positive 36-week maintenance data for its REZOLVE-AD Phase 2b trial and closing a large public equity and pre-funded warrant offering to fund late-stage development.
See our latest analysis for Nektar Therapeutics.
The latest REZOLVE-AD readout and follow on equity offering arrive after a sharp shift in sentiment, with a 7 day share price return of 92.42% and a 1 year total shareholder return of roughly 4x. However, the 5...